Neoantigen-Based Therapies Summit US 2022

Returning for the 7th year, the Neoantigen-Based Therapies Summit remains your comprehensive guide to transforming the clinical development of cell and vaccine based neoantigen therapies.

URLs:
Website: https://go.evvnt.com/1257931-0?pid=176
Tickets: https://go.evvnt.com/1257931-2?pid=176
Brochure: https://go.evvnt.com/1257931-3?pid=176

Prices:
Drug Developer Pricing (Full Access: Conference + 2 Workshops): USD 3697.00,
Drug Developer Pricing (Conference + 1 Workshop): USD 3148.00,
Drug Developer Pricing (Conference Only): USD 2599.00,
Academic Pricing (Full Access: Conference + 2 Workshops): USD 3097.00,
Academic Pricing (Conference + 1 Workshop): USD 2648.00,
Academic Pricing (Conference Only): USD 2199.00,
Service Provider Pricing (Full Access: Conference + 2 Workshops): USD 5097.00,
Service Provider Pricing (Conference + 1 Workshop): USD 4348.00,
Service Provider Pricing (Conference Only): USD 3599.00

Speakers: Stefan Scherer, Chief Executive Officer, 3T Biosciences, Jian Yan, Vice President, Research and Discovery, Geneos Therapeutics, Ramon Tiu, Head Of Oncology Cell Therapy Development, Takeda, Heinz Lubenau, Chief Drug Development Officer, NEC OncoImmunity, Christopher Gallen, Executive Chairman and Chief Executive Officer, Treos Bio, Sandra Gabelli, Executive Director - Structural Chemistry, Merck, Wigard Kloosterman, Chief Scientific Officer, Frame Therapeutics, Agnete Fredriksen, Chief Innovation and Strategy Officer, Nykode Therapeutics, Eli Gilboa, Professor - Microbiology and Immunology, School of Medicine, University of Miami, Elisa Scarselli, Chief Scientific Officer, Nouscom, Eric Halioua, President and Chief Executive Officer, PDC*line Pharma, Guilhem Richard, Chief Technology Officer, EpiVax Therapeutics, Jeff Bockman, Executive Vice President and Head of Oncology, Lumanity, Jens Kringelum, Director Genomic Immuno-Oncology, Evaxion, Jeroen van Bergen, Chief Scientific Officer, Immunetune, Joel Sandler, Principal Cancer Cell Therapy Lead, Lumanity, Kaïdre Bendjama, Project Leader - Personalized Cancer Vaccines, Transgene, Matt Davis, Director of NGS, Gritstone bio, Niranjan Sardesai, Co-Founder, President and Chief Executive Officer, Geneos Therapeutics, Muna Abdullahi, Research Analyst, Beacon Targeted Therapies, Paola Bonaventura, Project Leader Oncoimmunology, ErVaccine Technologies, Karin Jooss, Head of Research and Development, Gritstone bio, Nicole Ruggiero, Chief Executive Officer, EpiVax Therapeutics, Philip Arlen, President and Chief Executive Officer, Precision Biologics, Sergio Quezada, Chief Scientific Officer, Achilles, Stephen Albert, Johnston Founding Chief Executive Officer, Calviri

Time: 7:00 am to 4:00 pm